How many drugs treat Transitional cell carcinoma?

Drug Landscape tracks 4 marketed treatments for Transitional cell carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/transitional-cell-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Transitional cell carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transitional cell carcinoma (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Transitional cell carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Imfinzi	durvalumab	AstraZeneca	Programmed Death Ligand-1 Blocker [EPC]	Programmed cell death 1 ligand 1	2017-01-01
Tecentriq	atezolizumab	Roche	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death 1 ligand 1	2016-01-01
Opdivo	nivolumab	Bristol-Myers Squibb	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death protein 1	2014-01-01
Imfinzi	Imfinzi	University Medical Center Groningen		Programmed cell death 1 ligand 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 1 drug in Transitional cell carcinoma
Bristol-Myers Squibb · 1 drug in Transitional cell carcinoma
Roche · 1 drug in Transitional cell carcinoma
University Medical Center Groningen · 1 drug in Transitional cell carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Transitional cell carcinoma:

Cite this brief

Drug Landscape (2026). Transitional cell carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/transitional-cell-carcinoma. Accessed 2026-06-10.

Transitional cell carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing